mRNA Purity Analysis Service
The clinical efficacy and safety profile of messenger RNA (mRNA) therapeutics are inextricably linked to the purity of the drug substance. During the in vitro transcription (IVT) process, various process-related impurities are generated, including double-stranded RNA (dsRNA), truncated mRNA sequences, and residual DNA templates. These impurities can trigger unintended innate immune responses or reduce the translational efficiency of the genetic payload. CD BioGlyco provides a high-resolution mRNA purity analysis service that utilizes multi-orthogonal analytical platforms to quantify and characterize impurities with unmatched precision. By partnering with us, you gain access to a purity map that mitigates development risks and accelerates the path to the clinic.
Our analytical suite integrates sophisticated biophysical and biochemical methods to detect even trace-level contaminants in complex mRNA mixtures.
A high-resolution separation technique that utilizes specialized stationary phases and ion-pairing agents to resolve mRNA species based on length and hydrophobicity.
Utilizing laser-induced fluorescence, this technology provides superior resolution for distinguishing full-length mRNA from truncated or degraded fragments across a wide molecular weight range.
A label-free, single-molecule technique that measures the mass distribution of the mRNA population in its native state, identifying aggregates and large-scale impurities.
Provides precise mass measurements of intact mRNA molecules, allowing for the direct identification of chemical modifications and stoichiometry of contaminants.
Targeted detection of immunogenic dsRNA byproducts using specialized antibodies and advanced detection platforms to ensure inflammatory markers remain below safety thresholds.
Upon receipt, our specialists conduct a thorough physicochemical assessment of your mRNA sample. Using fluorometric and spectrophotometric methods, we precisely determine concentration and evaluate buffer composition (e.g., salts, stabilizers). This initial profiling allows us to tailor the optimal dilution factor and necessary buffer-exchange steps, ensuring your sample is perfectly conditioned for downstream high-sensitivity analysis without introducing artifacts or signal interference.
Samples are analyzed using complementary high-resolution techniques: IP-RPLC and/or CGE-LIF. We apply proprietary, method-specific gradient and polymer matrix optimizations to achieve maximum resolution. This fine-tuned separation clearly resolves the main full-length mRNA peak from closely eluting or migrating impurities, such as truncated fragments, oversized species, or process-related nucleotides, providing a clean baseline for accurate quantification.
Our advanced analytical software automatically processes the chromatographic and electrophoretic data, performing precise peak integration and baseline correction. It calculates the primary percentage purity of the full-length mRNA product and separately quantifies key impurity classes, including dsRNA, residual DNA template, and incomplete capping species. This detailed breakdown highlights not just how much intact mRNA is present, but precisely what impurities may impact safety or efficacy.
To complement separation-based purity data, we employ orthogonal, label-free techniques such as mass photometry or native mass spectrometry. These methods directly measure the molecular mass and homogeneity of the mRNA population in solution, enabling the detection of large aggregates, non-covalent complexes, or significant mass variants that may not be resolved by chromatography or electrophoresis alone, providing a more holistic view of product quality.
Every dataset undergoes a rigorous, multi-step review by our PhD-level scientists. This includes cross-referencing results from the different analytical platforms (e.g., correlating purity percentages from IP-RPLC with aggregate levels from mass photometry) to ensure internal consistency, accuracy, and reproducibility. Any discrepancies are investigated, guaranteeing that the final purity assessment is robust, reliable, and scientifically defensible.
You will receive a finalized analytical dossier. This report includes all processed chromatograms/electropherograms, the associated raw data files, clearly interpreted graphs with annotated impurities, and a concise executive summary that highlights the critical quality attributes (CQAs).
Journal: Molecules
DOI: 10.3390/molecules30071629
IF: 4.6
Published: 2025
Results: In this comprehensive review, Camperi et al. systematically evaluate the current landscape of analytical techniques essential for the characterization of mRNA-based therapeutics, emphasizing the critical need for robust methods to ensure the identity, purity, stability, and functionality of these complex molecules. The authors meticulously detail the principles, applications, advantages, and limitations of a wide array of technologies, including electrophoresis (e.g., capillary gel electrophoresis), chromatography (e.g., ion-pair reversed-phase liquid chromatography, size exclusion chromatography), mass spectrometry (both ensemble and single-particle approaches like charge detection mass spectrometry), and advanced sequencing platforms (Illumina, PacBio, Oxford Nanopore). They highlight how these orthogonal methods are employed to assess key quality attributes such as sequence integrity, 5' capping efficiency, poly(A) tail length, and the presence of impurities like double-stranded RNA. The review underscores that no single method is sufficient for full characterization, advocating instead for a complementary toolkit. By providing a comparative analysis of these advanced strategies, the work serves as a vital resource for guiding the development, quality control, and regulatory approval of mRNA therapeutics, thereby supporting the rapid growth and application of this promising therapeutic modality.
Cancer Immunotherapy
For neoantigen-based therapies, our purity analysis ensures that the small-scale batches produced for individual patients are free from truncated sequences that could lead to non-functional protein expression.
In Vivo Gene Editing
Purity analysis of mRNA encoding CRISPR-Cas9 or other nucleases is vital to ensure that the transient expression is sufficient for editing while maintaining a high safety margin within target cells.
Manufacturing Process Scale-Up
During the transition from lab-scale to pilot-scale production, our purity mapping identifies potential bottlenecks or changes in impurity profiles, ensuring the quality remains constant during industrialization.
RNA-Based Adjuvant Research
We assist researchers in characterizing the purity of non-coding RNA molecules used as adjuvants, ensuring that their stimulatory effects are due to the intended sequence rather than contaminants.
Multi-Orthogonal Analytical Verification
We don't rely on a single method; our service combines IP-RPLC and CGE-LIF to provide cross-validated purity data, ensuring that no hidden impurities are overlooked during the assessment process.
High-Resolution Truncation Mapping
Our optimized capillary electrophoresis protocols can resolve truncated mRNA species that differ by only a few nucleotides from the full-length transcript, providing a granular view of IVT fidelity.
Native State Characterization
Utilizing mass photometry allows us to analyze mRNA purity in its natural folded state, identifying aggregates and degradation products without the need for harsh denaturing conditions that might mask certain impurities.
Optimized Sample Recovery
Our micro-analytical workflows require minimal sample volumes, preserving your valuable mRNA for downstream applications while still providing a reliable purity profile for your drug substance.
CD BioGlyco's ability to quantify dsRNA in our vaccine batches was a game-changer. Their data allowed us to optimize our purification process and significantly reduce the reactogenicity of our candidate.
— By Dr. J.A., Senior Scientist, Immunology Department
The purity reports from CD BioGlyco are consistently high-quality and easy to interpret. The multi-orthogonal approach gave us the confidence we needed to move our mRNA program into the next phase of development.
— By Manager of Quality Control, Biopharma Division
We were struggling with low expression in our CAR-T cells until we used CD BioGlyco for purity analysis. They identified a significant amount of 3'-truncated mRNA that our internal tools had missed.
— By Dr. L. Zhang, Lead Researcher, Gene Therapy Group
Characterize the binding kinetics and cellular uptake of your mRNA molecules to ensure effective delivery.
Evaluate the potential for unintended gene regulation or immune activation by your mRNA therapeutic.
Measure the biological activity and potency of mRNA-lipid or mRNA-peptide conjugates.
Comprehensive analysis of the absorption, distribution, metabolism, and excretion of your mRNA-based products.
CD BioGlyco is committed to providing the highest standard of analytical excellence for the global RNA therapeutic community. Our mRNA purity analysis service empowers researchers and developers with the data needed to ensure product safety and efficacy. Whether you are in the discovery phase or preparing for clinical manufacturing, contact us!
Reference
